Intl. Filing Date: 13 August 2004

Response to Final Office Action mailed March 16, 2010

Page 2

CLAIMS

1.-43. (Canceled).

23. (Currently Amended) A compound of formula I

$$R^{1}$$
 R^{0}
 R^{5}
 R^{6}
 R^{7}
 R^{8}
 R^{2}
 R^{3}
 R^{4}
 R^{4}
 R^{10}

wherein

each of R^0 , R^1 , and R^2 , and R^3 independently is hydrogen, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$,

(I)

 $-NR_{12}S(O)_{0\text{--}2}R_{13}\text{[, and]}\ \underline{or}\ -C(O)NR_{12}R_{13};$

R^3 is $-S(O)_{0-2}R_{13}$ or $-C(O)NR_{12}R_{13}$:

wherein R_{12} is selected from hydrogen and C_{1-6} alkyl; and R_{13} is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl[,];

R⁴ is hydrogen;

each of R⁵ and R⁶ independently is hydrogen[,] or halogen[,]; and

each of R⁷, R⁸, R⁹, and R¹⁰ independently is ethoxy, ethyl, propyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, isobutyloxy, t-butyloxy, isopropyloxy, methylamino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, -XR₁₁, -C(O)R₁₁ [and] or -OXR₁₁; wherein X is a bond, methylene or ethylene; R₁₁ is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R₁₁ is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino[,];

wherein one of R⁷, R⁸ and R⁹ independently of each other can also be hydrogen;

Intl. Filing Date: 13 August 2004

Response to Final Office Action mailed March 16, 2010

Page 3

A is C; or salts thereof.

24. (Currently Amended) A compound of formula I according to claim 23, wherein each of R⁰ or R² independently is hydrogen;

R¹ is hydrogen; and

R³ is selected from dimethyl sulfamoyl, isobutyl sulfamoyl, methyl sulfamoyl, ethyl sulfamoyl, propyl-sulfonyl, ethyl-amino-carbonyl, 1 ethyl propyl sulfamoyl, cyclopentyl sulfamoyl, isopropyl-sulfamoyl, cyclohexyl-sulfonyl, eyelopropyl-methyl-sulfamoyl, cyclobutyl-sulfamoyl, and isopropyl-sulfonyl.

25.-32. (Canceled).

- 33. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 23, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.
- 34. (Previously Presented) A combination comprising a therapeutically effective amount of a compound according to claim 23 and one or more further known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.
- 35. (Previously Presented) A method for the treatment of breast tumor in a subject in need thereof which comprises administering an effective amount of a compound according to claim 23.

36-43. (Canceled)

Intl. Filing Date: 13 August 2004

Response to Final Office Action mailed March 16, 2010

Page 4

44. (New) A compound of Formula I'

$$R'_1$$
 N
 R'_2
 HN
 $(R'_3)_{n'}$
 I'

in which:

n' is selected from 1 and 2;

R'₁ is selected from phenyl, pyridinyl, pyrazolyl and pyrimidinyl; wherein any aryl or heteroaryl of R'₁ is substituted by 2 to 3 radicals independently selected from ethoxy, ethyl, propyl, methyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, isobutyloxy, t-butyloxy, isopropyloxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, -X'R'₄, -C(O)R'₄ and -OX'R'₄; wherein X' is a bond, methylene or ethylene; R'₄ is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl; wherein R'₄ is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino, methyl-amino and ethyl-amino.

R'2 is selected from hydrogen and halo;

R'₃ is selected from propyl-sulfonyl, ethyl-amino-carbonyl, cyclohexyl-sulfonyl, and isopropyl-sulfonyl;

or the pharmaceutically acceptable salts thereof;

with the proviso that this does not include any of the compounds of examples 1 to 52 inclusive.

45. (New) A pharmaceutical composition comprising a compound according to claim 44, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

Intl. Filing Date: 13 August 2004

Response to Final Office Action mailed March 16, 2010

Page 5

46. (New) A combination comprising a therapeutically effective amount of a compound according to claim 44 and one or more further known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

47. (New) A method for the treatment of breast tumor in a subject in need thereof which comprises administering an effective amount of a compound according to claim 44.